BUZZBERGAlpha Score combines three things: realized average return, confidence in the sample size, idea volume, and speaker reputation. Speakers with only a few calls are pulled closer to the platform average; speakers with many evaluated ideas keep more of their own return. Reputation only boosts: 5.0 or lower is neutral, while scores above 5 add weight. Scores are normalized to 0-100; 100 is best.Read the FAQ
ACHR is hiring 16% YoY, growing social media presence (IG up 18%), and has $2B in cash to fund commercialization. Positive alternative data metrics suggest internal confidence in their path to commercialization, with analysts projecting a $11 price target versus the current $6. A high-risk, high-reward "lottery ticket" play with 75% upside if they execute on their commercialization goals. Pre-revenue company; highly speculative with significant execution and regulatory risks.
ACHR is hiring 16% YoY, growing social media presence (IG up 18%), and has $2B in cash to fund commercialization. Positive alternative data metrics suggest internal confidence in their path to commercialization, with analysts projecting a $11 price target versus the current $6. A high-risk, high-reward "lottery ticket" play with 75% upside if they execute on their commercialization goals. Pre-revenue company; highly speculative with significant execution and regulatory risks.
LRCX is growing revenue 24% YoY with 29% net margins, job postings are up 62% in six months, and internal business outlook is at 94/100. High internal employee sentiment and aggressive hiring suggest management sees no impending slowdown, while recent Congressional buying adds a positive sentiment indicator. A stealthy semiconductor equipment play with strong internal momentum and financial health. Semiconductor equipment is highly cyclical; a broader macro downturn could halt capital expenditures.
LRCX is growing revenue 24% YoY with 29% net margins, job postings are up 62% in six months, and internal business outlook is at 94/100. High internal employee sentiment and aggressive hiring suggest management sees no impending slowdown, while recent Congressional buying adds a positive sentiment indicator. A stealthy semiconductor equipment play with strong internal momentum and financial health. Semiconductor equipment is highly cyclical; a broader macro downturn could halt capital expenditures.
VRT guided for 30%+ sales growth in 2026 with a $15B backlog, and LinkedIn job postings doubled from 1,000 to 2,000 in six months. Massive spikes in hiring velocity combined with surging orders (up 252%) indicate the company is aggressively expanding to meet data center demand, suggesting future earnings beats. Strong buy based on fundamental growth and alternative hiring data confirming the expansion. The stock has already rallied significantly ($54 to $277), making it vulnerable to multiple compression if growth slows.
VRT guided for 30%+ sales growth in 2026 with a $15B backlog, and LinkedIn job postings doubled from 1,000 to 2,000 in six months. Massive spikes in hiring velocity combined with surging orders (up 252%) indicate the company is aggressively expanding to meet data center demand, suggesting future earnings beats. Strong buy based on fundamental growth and alternative hiring data confirming the expansion. The stock has already rallied significantly ($54 to $277), making it vulnerable to multiple compression if growth slows.
Lithia Motors trades at ~8.9x forward P/E with its finance arm (Driveway Finance Corp) turning its first profitable year at $75M. The profitable finance arm adds a high-margin recurring revenue stream, and management's aggressive 11.4% share buyback signals strong internal conviction in the valuation gap. A deeply discounted auto retailer with significant upside to fair value estimates (Morningstar FV $387) and strong buyback support. A slowdown in consumer auto spending or rising defaults in their newly profitable finance arm.
Lithia Motors trades at ~8.9x forward P/E with its finance arm (Driveway Finance Corp) turning its first profitable year at $75M. The profitable finance arm adds a high-margin recurring revenue stream, and management's aggressive 11.4% share buyback signals strong internal conviction in the valuation gap. A deeply discounted auto retailer with significant upside to fair value estimates (Morningstar FV $387) and strong buyback support. A slowdown in consumer auto spending or rising defaults in their newly profitable finance arm.
Lennar trades at ~7x forward P/E, has a strong balance sheet ($2.1B cash, <15% debt-to-capital), and benefits from a 4 million US home deficit. The lock-in effect of 3% mortgages makes new builds the primary housing supply, while their recent asset-light spinoff and lower construction costs boost margins. A fundamentally cheap homebuilder with political insider buying and an upcoming spring selling season catalyst. Macroeconomic shocks to the housing market or persistently high interest rates dampening buyer demand.
Lennar trades at ~7x forward P/E, has a strong balance sheet ($2.1B cash, <15% debt-to-capital), and benefits from a 4 million US home deficit. The lock-in effect of 3% mortgages makes new builds the primary housing supply, while their recent asset-light spinoff and lower construction costs boost margins. A fundamentally cheap homebuilder with political insider buying and an upcoming spring selling season catalyst. Macroeconomic shocks to the housing market or persistently high interest rates dampening buyer demand.
Viatris trades at ~5.5x forward P/E following a major restructuring, debt paydown, and a 170% jump in open job positions. The massive spike in hiring indicates growth rather than maintenance, and the upcoming October FDA date for MR-141 presents a massive TAM opportunity. A deeply undervalued turnaround play with strong institutional backing and a major pipeline catalyst. FDA rejection of MR-141 or failure to execute on the post-restructuring growth strategy.
Viatris trades at ~5.5x forward P/E following a major restructuring, debt paydown, and a 170% jump in open job positions. The massive spike in hiring indicates growth rather than maintenance, and the upcoming October FDA date for MR-141 presents a massive TAM opportunity. A deeply undervalued turnaround play with strong institutional backing and a major pipeline catalyst. FDA rejection of MR-141 or failure to execute on the post-restructuring growth strategy.